Article
Second-line Afatinib or Chemotherapy Following Immunochemotherapy for the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: Real-world Effectiveness and Safety From a Multisite Retrospective Chart Review in the USA.
Clinical lung cancer - 1 Jul 2021
Kim Edward S, Kish Jonathan K, Cseh Agnieszka, Moehring Barbara, Tang Wenbo, Terlizzi Elizabeth, Subramanian Janakiraman
Abstract excerpt
BACKGROUND: The ErbB family blocker, afatinib, is approved for patients with squamous cell carcinoma (SqCC) of the lung following platinum-doublet chemotherapy but has not been explored following immunochemotherapy. Here, we assessed the characteristics and outcomes of patients with SqCC of the lung who received second-line afatinib or chemotherapy after first-line pembrolizumab plus chemotherapy in a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.